Radiopharm Theranostics (RDPTF) Total Non-Current Liabilities (2024 - 2026)

Radiopharm Theranostics (RDPTF) has reported Total Non-Current Liabilities for 3 consecutive years, with $134159.5 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Non-Current Liabilities fell 26.95% year-over-year to $134159.5 in Q2 2026; TTM through Jun 2026 was $134159.5, a 26.95% decrease from a year earlier, with the FY2026 full-year figure at $128449.0, down 99.55% from the prior year.
• Total Non-Current Liabilities was $134159.5 for Q2 2026 at Radiopharm Theranostics, down from $183656.9 in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $27.3 million in Q4 2024 and troughed at $134159.5 in Q2 2026.
• A 3-year average of $6.9 million and a median of $181150.3 in 2024 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities grew 2.81% in 2025 and slipped 26.95% in 2026, its largest moves.
• Over 3 years, Total Non-Current Liabilities stood at $27.3 million in 2024, then plunged by 99.33% to $183656.9 in 2025, then dropped by 26.95% to $134159.5 in 2026.
• The last three Total Non-Current Liabilities figures came in at $134159.5 (Q2 2026), $183656.9 (Q2 2025), and $27.3 million (Q4 2024), per Business Quant data.